Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07226726

Enrollment

Registered

2025-11-10

Start date

2025-01-01

Completion date

2028-12-31

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Myasthenic Syndrome

Keywords

exosomes, secretome, Congenital Myasthenic Syndrome

Brief summary

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Detailed description

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

Interventions

BIOLOGICALAlloEx exosomes

This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician. * Patients must be able to provide informed consent, or have a guardian who does. * Patient must be able to travel to the site of treatment.

Exclusion criteria

* Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.

Design outcomes

Primary

Measure	Time frame
Oxygen Saturation	From enrollment to 6 months after treatment

Countries

Antigua and Barbuda, United States

Contacts

Primary ContactChadwick Prodromos

care@thepsci.com18476996810

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026